NDA 018413 · Chartwell Rx
Furosemide
Furosemide · Oral · Loop Diuretic
DiscontinuedLast checked: Nov 20, 2026Latest source record: Aug 7, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
Nov 30, 1983
Approved uses
1
Original approval plus efficacy supplements
Registered trials
345
66 Phase 3, 33 recruiting
FAERS reports
265,537
219,231 serious, 40,876 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 26, 2025.
INDICATIONS AND USAGE Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 30, 1983 Original approval
2 products under this application
- FUROSEMIDE · FUROSEMIDE 40MG · TABLET, ORAL · Discontinued
- FUROSEMIDE · FUROSEMIDE 20MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Furosemide" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Platform of Randomized Adaptive Clinical Trials in Critical IllnessPivotal-lookingRecruiting
University Health Network, TorontoAcademic, hospital or other
NCT05440851 · 6,250 participants (planned) · Start Apr 30, 2023 · Primary completion Mar 31, 2027
Drug: Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose and 6 more · For: Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 103 sites in all
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
- TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart FailurePivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03296813 · 2,973 participants · Start Jul 11, 2018 · Primary completion Jul 29, 2022
Drug: Torsemide; Furosemide · For: Heart Failure
Sites: Alexander City, Alabama; Huntsville, Alabama; Tucson, Arizona · 60 sites in all
- Effects of Fluid Balance Control in Critically Ill PatientsPivotal-lookingCompleted
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT02765009 · 1,411 participants · Start Jun 1, 2016 · Primary completion Jul 31, 2019
Drug: diuretics; albumin · For: Fluid Shifts; Critical Care
Sites: Belfort, France; Dijon, France; Lyon, France · 11 sites in all
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS StudyPivotal-lookingCompleted
Heart Care FoundationAcademic, hospital or other
NCT00421863 · 1,111 participants · Start Feb 2005 · Primary completion Jan 2009
Drug: Triatec 10 mg; Triatec HCT 5 and 7 more · For: Hypertension
Sites: San Pietro Vernotico, Italy; Chiari, Italy; Trebisacce, Italy · 45 sites in all
- Acetazolamide or Metolazone in Acute Heart FailurePivotal-lookingNot yet recruiting
Clinica Alemana de SantiagoAcademic, hospital or other
NCT06273397 · 1,050 participants (planned) · Start May 1, 2024 · Primary completion Mar 1, 2027
Drug: Acetazolamide 250 MG; Metolazone 2.5 MG and 1 more · For: Heart Failure Acute; Decompensated Heart Failure
- DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart FailurePivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05276219 · 1,041 participants (planned) · Start Sep 14, 2023 · Primary completion May 1, 2027
Drug: Furosemide Injection; Isosorbide Dinitrate and 1 more · For: Pulmonary Edema; Congestive Heart Failure; Acute Heart Failure
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea18,437
- acute kidney injury16,467
- fatigue13,248
- diarrhoea13,195
- death12,368
- nausea11,534
- fall11,003
- off label use10,842
- drug ineffective10,424
- hypotension10,330
- pneumonia10,172
- dizziness9,887
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,479 |
| 2005 | 3,857 |
| 2006 | 3,623 |
| 2007 | 3,214 |
| 2008 | 3,608 |
| 2009 | 3,997 |
| 2010 | 4,832 |
| 2011 | 6,479 |
| 2012 | 7,274 |
| 2013 | 7,405 |
| 2014 | 10,059 |
| 2015 | 13,254 |
| 2016 | 16,201 |
| 2017 | 16,716 |
| 2018 | 21,192 |
| 2019 | 23,004 |
| 2020 | 20,355 |
| 2021 | 18,734 |
| 2022 | 16,306 |
| 2023 | 16,473 |
| 2024 | 17,411 |
| 2025 | 16,227 |
| 2026 | 11,830 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Furosemide* (Furosemide)
2024 spending
$119M
Beneficiaries
5,790,198
23,553,663 claims
Per beneficiary
$21
$0.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $147,144,669 |
| 2021 | $140,004,881 |
| 2022 | $139,702,947 |
| 2023 | $144,867,352 |
| 2024 | $118,928,717 |
Part B: Furosemide (Furosemide) · HCPCS J1940
2024 spending
$30K
Beneficiaries
16,747
27,644 claims
Per beneficiary
$2
2024 ASP limit $0.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $50,841 |
| 2021 | $44,701 |
| 2022 | $40,222 |
| 2023 | $37,593 |
| 2024 | $29,817 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis.
Lee TH, Kuo G, Chang CH, et al. · PLoS One 2021 · Comparative Study, Meta-Analysis
- Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials.
Ng KT, Yap JLL · Anaesthesia 2018 · Comparative Study, Meta-Analysis
- Postpartum furosemide for accelerating recovery in patients with preeclampsia: a randomized placebo-controlled trial.
Cursino T, Katz L, Coutinho I, et al. · Am J Obstet Gynecol MFM 2025 · Randomized Controlled Trial
- Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
Mentz RJ, Anstrom KJ, Eisenstein EL, et al. · JAMA 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Furosemide chronopharmacology.
Meyer BH, Müller FO, Gray IP, et al. · S Afr Med J 1982 · Clinical Trial, Controlled Clinical Trial
- Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intrapatient Comparison of 3 Diuretic Regimens (DEA-HF).
Abbo AR, Gruber A, Volis I, et al. · JACC Heart Fail 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Chartwell Rx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.